INTRODUCTION
A cardinal feature of Parkinson's disease (PD) is the loss of dopaminergic neurons in the substantia nigra, leading to a decrease in axonal connections to the striatum. The resulting loss of dopamine causes the motor, and some non-motor symptoms. Increasing the presence of dopamine in the target areas of the putamen is one way to restore some of the lost function.
This restoration can be achieved in several ways, by reintroduction of dopaminergic neurons via implanted stem cells; stimulation of neuron regrowth and/or awakening via infusion of exogenous molecules, e.g. Glial CellDerived Neurotrophic Factor (GDNF); or gene therapy, the introduction of engineered DNA sequences able to code for in situ production of the relevant molecule. This article will briefl y summarize the current approach to gene therapy for Parkinson's and then describe the projects currently in the clinic.
The feasibility of gene therapy has been proven clinically, in indications such as Spinal Muscular Atrophy (SMA) [1] , lysosomal storage diseases [2] and hereditary leukodystrophy [2] . As unprotected DNA or RNA sequences are rapidly degraded and are thus not feasible, these therapies use a delivery vehicle which in most cases is a viral vector, usually Adeno-Associated Virus (AAV) or Lentivirus (LV).
An excellent review of the therapeutic use of AAV in the nervous system was recently published by Huidry and Vandenberghe [2] . Many years of pre-clinical and now clinical experience have demonstrated the safety and effi cacy of AAV. It is easily manipulated to insert the desired sequence with little residual viral DNA. It has rarely been shown to integrate into the host genome, primarily existing as episomal DNA, with the viral particles unable to replicate and devoid of viral genes. Lentivirus-delivered sequences can integrate into the host genome, but only in non-dividing cells.
The highest technical hurdle for any gene therapy is delivering the engineered virus to the target tissue. In the context of Parkinson's, where the targets lie either deep inside the brain or widely located in the periphery, The advantage of gene therapy over infusion of molecules such as GDNF is that, in practice thus far and in theory in the future, only one administration of drug product is needed for long-term biological activity. The addition of a double-blind placebo arm is also easier as simple sham surgery without dura penetration is possible. Whilst it may be easier, it is still not easy and the logistics of surgical delivery bring complications to the design, conduct and funding of clinical trials.
The therapeutic benefi ts of gene therapy for Parkinson's must also be assessed in the context of the symptom relief provided by Deep Brain Stimulation (DBS), for both effi cacy and safety. While gene delivery still requires a surgical intervention, it offers a potentially attractive alternative to DBS as there is no requirement for an implantable device or postoperative programming.
Finally, it must be stressed that none of the gene therapy projects currently in trial can be classifi ed as a "cure". They are highly unlikely to infl uence disease pathology, whether that is a-synuclein aggregation, LRRK2 malfunction or another route. Dysfunction in other neurotransmitter routes will continue with residual motor and continued non-motor symptoms. This is not to underplay the importance and potential of gene therapy in Parkinson's. The potential to deliver longterm motor (and some non-motor) symptom relief with greater ON time, reduced dyskinesia and signifi cantly improved quality of life from a single surgical procedure will be extremely attractive. After all, if People with Parkinson's (PwP) retain the pathology but can't feel it, why should we care?
GENE THERAPIES IN THE CLINIC
There are fi ve gene therapy programmes currently in the clinic, in phase 1 or 2, designed to deliver either biosynthetic enzymes or growth factors. Three projects aim to induce synthesis of dopamine, one to make gamma-amino butyric acid (GABA) and one to introduce GDNF.
Voyager Therapeutics in the USA and Jichi Medical University with Takara in Japan use AAV to deliver the gene for amino acid decarboxylase (AADC), the enzyme that converts levodopa to dopamine. Axovant's AxoLenti-PD, licensed from Oxford Biomedica, codes for two enzymes that synthesize dopamine -AADC and tyrosine hydroxylase (TH) -and GTP cyclohydrolase 1 (GCH1), coding for production of an essential enzyme cofactor.
Axovant's phase 2 trial of Axo-Lenti-PD, SUNRISE-PD, is in phase 2, building on successful safety trials conducted by Oxford Biomedica on a previous version, ProSavin ® . Jichi's AAV-HAADC-2 is in phase 1/2, following on from a successful phase 1 trial in inherited AADC defi ciency.
MeiraGTx are developing AAV-GAD, which codes for glutamic acid decarboxylase (GAD), an essential enzyme for GABA synthesis. Neurologix had previously taken this potential therapy to a Phase 2 trial prior to the company folding. MeiraGTx acquired the rights from Vector Neurosciences and plan to continue phase 2 studies.
The National Institutes of Neurological Disorders and Stroke (NINDS) in the USA are developing AAV-GDNF, currently in Phase 1, involving a smaller open-label cohort primarily testing safety. Finally, Prevail Therapeutics are investigating AAV vectors to correct lysosomal malfunction in Parkinson's, although the date of entry to clinical trials is as yet unknown.
The site of delivery is the striatum, primarily the putamen, in all of the projects except one; AAV-GAD is targeted at the sub-thalamic nucleus (STN) in an effort to reduce the overactivity seen in Parkinson's. All of the therapies have a single surgical procedure with no further infusions.
The duration of treatment and observation varies. Axovant will assess safety at 3 months and effi cacy (as a secondary outcome) at 6 months. Jichi will assess both at 6 months and Voyager at 12 months post-operation. NINDS will assess both at regular intervals over 12 years. The details of MeiraGTx's next study are not yet available.
Primary outcomes are all on safety measures, with one exception. Voyager's AAV2-hAADC has an additional assessment of effi cacy, measuring the patient-rated change in ON time without dyskinesia. UPDRS and PDQ-39 are both secondary outcome measures. The Axovant study has only three secondary outcomes, all on effi cacy.
The more advanced a patient is in the course of their condition, the greater the therapeutic range over which improvement may be detected. All the studies are looking for moderately advanced patients, with a minimum duration of disease of 5 years (4 years in the Voyager study). In addition, Axovant are actively seeking patients with motor fl uctuations and dyskinesia.
The time to study end is highly variable. Voyager's RESTORE-1 started in 2018 and will fi nish in 2020, with a separately listed follow up trial ending in 2026. The NINDS trial started in 2012 and is targeted to complete in 2026. Axovant's follow up is to 2031, with primary reporting in 2022. From the perspective of PwP, the time taken to complete these phase 2 studies with phase 3 still to come is highly frustrating, although the prospect exists for phase 3 to run in parallel with the follow up stage of phase 2.
In summary, the number of gene therapies in the clinic for Parkinson's is relatively small but builds on a generation of technical and clinical feasibility in this and other indications. The complexity of drug administration limits the numbers of patients that can be included in clinical trials. The direct delivery to the anatomy of choice holds great potential for signifi cant therapeutic benefi t and symptom relief with reduced motor complications. 
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AAV-hAADC -Jichi Medical University
BACKGROUND: Aromatic amino acid decarboxylase (AADC) converts both endogenous and exogenous levodopa to dopamine in the nigro-striatal region. AADC activity is reduced along with reduced production of dopamine as a function of a progressive nigrostriatal degeneration with advancing disease. This in turn reduces conversion of exogenous levodopa to dopamine leading to increased dose requirement which can be limited due to potential complications. Gene therapy transducing production of AADC alone in the striatum may help restore the enzymatic activity and may be able to reduce the dose of exogenous levodopa but cannot restore the endogenous levodopa production. There are two programs, Jichi University in Japan and Voyager Therapeutics in the USA currently conducting early phase studies of AADC gene delivery in PD.
A small Phase I study was conducted in Japan demonstrating acceptable safety/tolerability and trends for effi cacy [1] . The group has since then launched a phase 1/2 dose escalation study. 
OBJECTIVE:
To evaluate the safety and effi cacy of intra-putaminal infusion of AAV-hAADC-2 (adenoassociated virus encoding human aromatic L-amino acid decarboxylase) delivered via stereotaxic surgery in advanced PD patients.
STATUS:
Recruiting.
CLINICALTRIALS.GOV IDENTIFIER: NCT02418598.
SPONSOR: Jichi Medical University.
COLLABORATOR:
Takara Bio Inc. Gene Therapy Research Institution, Co., Ltd.
ESTIMATED ENROLMENT: 6 (Phase 1 cohort).
ESTIMATED PRIMARY COMPLETION DATE:
October 2018 according to clinicaltrials.gov though no results have yet been posted.
STUDY DESIGN:
This study is a phase 1/2 non-randomized, single center, open label, interventional, safety and dose evaluation study of the active agent AAV-hAADC-2 being delivered intra-putaminal via stereotaxic surgery. It is being conducted at the Jichi Medical University in Japan. The target putamen is identifi ed on the pre-operative MRI brain and then bilateral putamina are infused with the active drug at a total of 4 spots (2 on each putamen). AAV-hAADC-2 is administered via bilateral intra-putaminal infusion in either low or high dose.
There are two sequential study arms. Cohort 1 receives low dose (3x10 11 vector genome/subject) and is infused with a total volume of 200 µl of the drug (50 µl per site). If there are no safety concerns at 6 months, then the study moves to cohort 2. Cohort 2 will receive high dose (9x10 11 vector genome/subject) with 600 µl of total infusion volume (150 µl per site).
The study includes patients with clinical diagnosis of idiopathic PD aged between 35 to 75 years of age with no other known or suspected cause of parkinsonism. Patients should be levodopa responsive and should have been on it for at least 5 years. An OFF state MDS-UPDRS score between 30 -100 and Hoehn and Yahr stage IV is required. Patients with a history of 3 hours or more of intensive or violent dyskinesia are excluded from the study. Standard surgical exclusionary criteria are applied. OUTCOME: Primary outcome measures include assessment of safety of intra-putaminal infusion of AAVhAADC-2 as measured by adverse events.
Secondary outcomes include two measures:
1. The treatment effect of the drug at the end of 6 months. This is assessed by improvement in PD symptoms as recorded in subject diaries, clinical assessment and change in levodopa dosage. 2. The amount of intra-putaminal expression of AAV-hAADC-2 after 6 months, as measured by FMT-PET imaging.
Investigators will continue to assess the safety for 5 years after baseline examination and long term follow up will continue for 10 years.
COMMENTS: This is a phase 1/2 dose escalation safety and effi cacy study. No results have been published yet. Voyager Therapeutics is further ahead in their development program that is reviewed below. 
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VY-AADC02 -VOYAGER THERAPEUTICS
BACKGROUND: Voyager Therapeutics are developing VY-AADC02, an AAV-2 vector coding for aromatic l-amino acid decarboxylase (AADC). It is delivered surgically to the putamen where, once expressed, AADC converts levodopa to dopamine.
Two phase 1 studies (NCT01973543 and NCT03065192) evaluated the safety of escalating doses of VY-AADC01, a precursor of VY-AADC02. The Phase 1b, open-label, three dose-escalation trial included 15 patients with advanced Parkinson's Disease (an average of 10 years post-diagnosis) and disabling motor fl uctuations, despite treatment with optimal anti-parkinsonian medications.
Putaminal coverage (as measured by co-administration of the MRI contrast agent, gadoteridol) was up to 42%. AADC activity increased by up to 79% as measured by 18 F fl uoro-L-DOPA PET. After 18 months, results showed an increase in ON time without troublesome dyskinesia of 2.4 hours in the combination of cohorts 2 and 3. These results were achieved with clinically meaningful and sustained reductions in daily oral levodopa and related medications of up to 42% [1] . Infusions of VY-AADC have been well-tolerated in all 15 patients treated in these cohorts, with no reported vector-related serious adverse events (SAEs).
This progress enabled Voyager to start the phase 2 RESTORE-1 study summarized below. Patients from the earlier phase 1 studies and RESTORE-1 will be invited to participate in a long-term follow up observational safety study (NCT03733496).
Voyager have now agreed with the FDA to increase the number of patients in RESTORE-1 to 75-100 and to commence another trial of similar size and design, RESTORE-2, to act as a staggered-parallel phase 3 study. Together with the granting of RMAT (Regenerative Medicine Advanced Therapy) status, this will hopefully be suffi cient to enable regulatory submission of the full package [2] . 
STUDY DESIGN:
Voyager's phase 2 study is randomized, placebo-controlled and double-blind, comparing one active dose of VY-AADC02 with a placebo of sham surgery involving a partial burr/twist hole without dura penetration. OUTCOME MEASURES: Primary outcomes will measure both effi cacy and safety. The safety criteria will be evaluated at 12 months and 30 day follow up. The effi cacy measures will be taken at 12 months, with enzyme activity also assessed at 45 days. The outcome measures are: a. change in patient rated motor fl uctuations. b. percent coverage within the putamen at time of administration of VY-AADC02. c. change in AADC enzyme activity (distribution 
COMMENTS:
Voyager are recruiting patients at least four years since diagnosis, although there is no explicit requirement for the presence of motor complications, despite the study title. The choice of primary and secondary outcome measures has some interesting features. The primary effi cacy outcome is a patient rating of motor fl uctuations, with UPDRS measures only as secondary outcomes.
The assessment of coverage of the putamen on administration and distribution of enzyme activity, both already validated in the phase 1b trial, will give a good indication of target engagement and change in biological activity. The combination of a good safety profi le thus far; the change in biological activity leading to signifi cant clinical change; and a favourable regulatory review, give cause for optimism with VY-AADC02. 
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MeiraGTx -AAV-GAD
BACKGROUND: Loss of substantia nigra pars compacta dopaminergic modulation of the basal ganglia circuitry results in reduction of inhibitory activity of the external globus pallidus (GP) via reduced GABAergic output. That translates into disinhibition of the subthalamic nucleus (STN), increasing its excitatory glutaminergic output to the internal GP which, coupled with over activity of the direct pathway, leads to over activity of the GPi and results in the motor symptoms of parkinsonism. Increasing inhibitory fl ow to the glutaminergic neurons in the STN may normalize its function and thereby lead to clinical benefi ts. Since glutamic acid decarboxylase (GAD) is the rate limiting step in the synthesis of GABA, the major inhibitory neurotransmitter, preclinical studies have explored injections of vectors containing GAD into the STN with promising results that lead to early phase human studies. Phase 1 and phase 2 studies have been completed.
NCT00195143 was a phase 1 open label trial assessing the safety and tolerability of AAV-GAD injections into unilateral STN in patients with PD. Three cohorts with 4 patients each received either low, medium or high dose AAV-GAD. There were no safety concerns and clinical benefi ts were noted in reduced motor UPDRS scores beginning at 3 months after the surgery and maintained at the 12 months assessment. PET scans revealed reduced thalamic metabolism on the implanted side which correlated with reduced pallidal activity [1] .
A subsequent phase 2, double-blind, randomized, sham surgery-controlled trial with bilateral STN injection of high dose (1x10 12 viral genomes) AAV-GAD was completed in 2010 and analysed data from 37 patients (NCT00643890). At the end of 6 months the AAV-GAD group showed signifi cant improvement in motor scores as compared to the sham group (23% reduction in the active group vs 13% in the sham, p< 0.003) with no treatment or surgery related adverse events. A 12-month analysis showed reduction of levodopa induced dyskinesias in the treated group. Furthermore, reduced metabolic activities on FDG-PET in the thalamus, striatum, prefrontal, anterior cingulate and orbitofrontal cortices were noted in AAV-GAD treated patients [2, 3] . A phase 3 trial was planned but was terminated by the sponsoring company Neurologix due to fi nancial reasons.
A recent analysis used the FDG-PET data from the phase 2 study to understand the metabolic brain network involved. The included patients had completed imaging visits at baseline, 6 and 12 months. The data suggested that the clinical improvement was not exerted via suppressing the abnormal PD related networks, but by developing new polysynaptic networks connecting STN to the cortices [4] .
In October 2018, MeiraGTx acquired the vector company (Vector Neurosciences Inc.) and as a result acquired clinical development of the AAV-GAD therapy [5] . According to the company website, a phase1/2 trial of AAV-GAD in PD patients is in the pipeline. No further information is available at this time and no trial is posted on clinicaltrials.gov.
COMMENTS:
The phase 1 and phase 2 clinical trials of AAV-GAD gene therapy have shown promising results. Both studies demonstrated an acceptable safety profi le of the drug and signifi cant effi cacy over shamcontrolled arm in the phase 2 trial though the effect size compared to sham was modest, a relative reduction of 10% in motor scores. The drug has now been acquired by MeiraGTx and a phase 1/2 study is in the pipeline.
AXO-Lenti-PD -AXOVANT
BACKGROUND: Axovant are developing AXO-Lenti-PD, previously known as OXB-102 when under development by Oxford Biomedica. OXB-102 was, in turn, a successor to ProSavin®. AXO-Lenti-PD uses a lentivirus vector to deliver three genes to the striatum in a single surgical procedure. The genes codes for three enzymes essential to the dopamine production cascade: amino acid decarboxylase (AADC), tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1(GCH1). The latter was shown to convert transduced nondopaminergic neurons into dopamine producing cells. The rationale for the treatment is to provide a cocktail of exogenously delivered enzymes to maximize endogenous dopamine production.
Oxford BioMedica successfully completed a phase 1/2 study for ProSavin®, which met its primary endpoint. The design was an open label dose escalation (NCT00627588), followed by a long-term observation study (NCT01856439). The results showed favourable safety and tolerability, with a statistically signifi cant improvement of motor function as measured by the UPDRS part III score at 6 and 12 months [1] . This improvement was sustained in most patients for up to six years [2] .
The FDA have confi rmed that the previous studies of ProSavin® can be considered as part of a single development program for AXO-Lenti-PD.
TITLE: Study of OXB-102 (AXO-Lenti-PD) in patients with idiopathic Parkinson's Disease (SUNRISE-PD).
STATUS: Recruiting.
CLINICALTRIALS.GOV ID: NCT03720418.
SPONSOR: Axovant.
ENROLMENT: 32 patients.
COMPLETION:
The primary completion target is June 2022, with full completion in December 2031.
STUDY DESIGN:
There are two parts to this phase 1/2 study. The fi rst is an open-label phase where three escalating dose levels will be tested. The second phase will take the optimal dose from part one into a randomized, double-blind phase in which patients will receive either active AXO-Lenti-PD or an imitation surgical procedure (ISP).
OUTCOME MEASURES:
Primary outcomes are all related to safety at the three-month time point, as measured by:
a. incidence of treatment emergent adverse events and serious adverse events. b. changes in clinical laboratory analysis. c. changes in vital signs. d. changes in brain MRI fi ndings. e. changes in physical examination.
Secondary outcomes are all related to effi cacy, as measured at the six-month timepoint by changes in: a. the Unifi ed Parkinson's Disease Rating Scale (UPDRS) scores compared to baseline in defi ned "OFF" and "ON" medication states. b. motor fl uctuations compared to baseline as assessed by patient diaries. c. the dyskinesia rating scale from baseline.
COMMENTS:
Axovant are recruiting patients at a relatively advanced stage of Parkinson's, with at least fi ve years since diagnosis and a Hoehn and Yahr stage of 3 or 4 in the OFF state. The patients must also be experiencing motor complications.
Results from the fi rst cohort using the lowest dose of AXO-Lenti-PD in two patients, were announced in March 2019 [3] , showing effi cacy greater than the highest dose of ProSavin® used in previous studies. No serious adverse events were reported. Clearly, caution must be applied given the number of patients and further results are awaited.
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AAV2-GDNF BACKGROUND:
Glial cell derived neurotrophic factors (GDNF) have been studied for more than a decade as potential neuroprotective interventions in PD. In preclinical models GDNF was shown to support the development of embryonic dopamine neurons (DA) and also to protect and restore mature DA of the substantia nigra in animal models. Though confl icting results exist, the weight of preclinical data is on the side of increased GDNF expression in the striatum during the late stages of PD with marked loss of DA and striatal connections [1] .
Further exploring the neuroprotective aspect of GDNF in PD, preclinical data in rat and primate models have positively shown the ability of transduced GDNF to induce sprouting from the lesioned axons or axon terminals. However, the positive meaningful effects were dependent on the location and timing of injection. Injecting the striatum during the early stage of disease process when the dopaminergic innervation of the striatum, particularly the putamen, is still relatively preserved was shown to have meaningful impact [2] . The promising neuroprotective benefi ts in the animal models supported the assessment of GDNF in human trials.
A number of studies explored the effi cacy of direct infusion of GDNF into the putamen and while open label studies were promising, not a single randomized study demonstrated effi cacy [3, 4] . One potential reason for failure was attributed to limitations of the direct putaminal delivery.
Gene vector delivery of GDNF is considered as a potentially more effi cient alternative. Another growth factor, neurturin, was studied with vector delivery into the putamen and substantia nigra but the studies were negative [5] . Sangamo therapeutics were conducting a phase 1/2 study of AAV-neurturin in PD (https://clinicaltrials. gov/show/NCT00985517) but the company has terminated the project.
A single on-going study is exploring gene delivery GDNF in PD: 
NINDS -AAV2-GDNF
TITLE
OBJECTIVE:
To assess the safety, tolerability and potential clinical effects of active drug AAV2-GDNF delivered by convection-enhanced delivery in advanced PD patients.
STATUS:
Active, not recruiting.
CLINICALTRIALS.GOV IDENTIFIER: NCT01621581.
SPONSOR: National Institute of Neurological Disorders and Stroke (NINDS).
ACTUAL ENROLMENT: 25.
ESTIMATED PRIMARY COMPLETION DATE: January 2022.
STUDY DESIGN: This is a phase 1 single center, open-label, dose escalation, safety and tolerability study of the AAV2-GDNF (adeno-associated virus, serotype 2 containing the human GDNF complementary DNA).
The active drug will be delivered surgically by convection-enhanced delivery to bilateral putamina. The study includes 4 cohorts to evaluate the four escalating dose levels. Each cohort will have 6 subjects. The drug level for each cohort is as follows: The study includes individuals 18 years and above with clinical idiopathic PD of at least 5 years disease duration with no other known or suspected cause for parkinsonism. An Off state UPDRS score of more than or equal to 30 and Hoehn and Yahr stage of III and IV are required for inclusion. The study also requires a 30% or greater improvement in the UPDRS total motor score on sinemet study according to the CAPSIT guidelines.
The participants in the study will be followed for 5 years with 18 outpatient study visits and a 3-day stay in the hospital post-surgery. Lumbar puncture for CSF analysis will be done at the time of surgery, 6 months and 18 months after surgery. OUTCOME: Primary outcome measure: To assess the safety and tolerability of 4 different dose levels of AAV2-GDNF over a period of 12 years.
Secondary outcome measures: To obtain preliminary data regarding the potential for clinical responses of the 4 dose levels testing by assessing the magnitude and variability of any treatment effects including clinical, laboratory and neuroimaging studies.
CURRENT STATUS: This is a phase 1 study looking at the safety, tolerability and potential clinical effi cacy of the drug. The group presented preliminary data at the American Association of Neurological Surgeons in April 2019 [6] . The data shows tolerability of the drug based on short and long term clinical and radiological assessment in the three cohorts (6, 6 and 1 patients in cohort 1, 2 and 3 respectively). The motor scores remained stable during the study period and PET imaging showed increased F-DOPA uptake in the infused areas at 6 and 18 months in 10/13 and 12/13 patients respectively. Data, as expected given it is a phase 1 study, are not suffi cient to suggest clinical effi cacy but supports the tolerability in the fi rst 3 escalating doses. Further trial is planned with intention to increase the putaminal coverage as preliminary data shows average coverage of 22% in the putamen.
COMMENTS: GDNF and neurturin have been studied extensively as potential neuroprotective interventions in PD so far with disappointing results despite reproducibly positive data in preclinical models. It remains to be determined if lack of success in PD clinical trials refl ects a lack of biological effect of intervention, limitations of the technical delivery modes (insuffi cient coverage of putamen, dose, etc) or failure to reverse the course of the advanced disease at the time of intervention. The ongoing study will be closely followed.
PHASE 3 STUDY IN FOCUS -INTEC PHARMA'S ACCORDION PILL
TITLE: A Study to Assess the Safety and Effi cacy of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients (Accordance).
STATUS:
CLINICALTRIALS.GOV ID: NCT02605434.
SPONSOR: Intec Pharma.
ENROLMENT: 420.
ESTIMATED COMPLETION DATE:
The primary completion date is August 2019.
OBJECTIVE:
The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than immediate release Carbidopa/Levodopa in reducing motor fl uctuations such as "off time" in advanced Parkinson's Disease patients.
BACKGROUND:
Levodopa remains the most potent symptomatic therapy for PD. One of the major limitations of levodopa therapy is the risk of development of motor fl uctuations and dyskinesia related to the short half life of the drug, coupled with progressive decline of neuronal dopamine storage capacity. Current formulations of levodopa are generally taken every few hours, leading to a pulsatile profi le of peaks and troughs. The peaks can induce troublesome dyskinesia while the troughs can lead to OFF time with signifi cant symptom breakthrough. A steadier and more consistent plasma profi le should reduce the incidence of both types of motor fl uctuation as well as reducing the number of tablets patients need to take.
Intec Pharma have developed the Accordion Pill, a gastric-retentive capsule containing multiple layers of both immediate release and controlled release levodopa and carbidopa. The pill remains in the stomach for up to 12 hours [1] .
In two phase 1 trials conducted in healthy adults, a single dose of Intec Pharma's AP-CD/LD provided more consistent levodopa plasma levels and less peak-trough fl uctuation than immediate release carbidopa/levodopa (IR-CD/LD) [2] . The safety of AP-CD/LD was similar to the known safety of CD/LD. AP-CD/LD should be taken with meals as it gives a more favorable pharmacokinetic profi le.
A phase 2 study (NCT00918177) in Parkinson's patients showed that peak-to-trough fl uctuations (mean Cmax -mean Cmin) with the AP CD-LD formulation were half of those with the reference product [1] . The levodopa morning plasma levels (pre-fi rst dose) were signifi cantly higher than those achieved with the IR-CD/LD (522ng/ µl vs. 68ng/µl). The high bioavailability of levodopa was preserved.
STUDY DESIGN and OUTCOMES
The phase 3 Accordance study is a multi-center (97 study locations), global, randomized, double-blind, doubledummy, active-controlled, parallel-group study in adult subjects with fl uctuating PD. The study will have 2 open label titration periods of 6 weeks each prior to the double-blind maintenance period. In the open label periods, all patients will be stabilized on the active comparator, IR-CD/LD and then on AP-CD/LD. The double-blind maintenance period will be 13 weeks long.
The primary outcome is change from baseline through to study completion, an average of 27 weeks, in the percentage of daily "Off time" during waking hours, based on Hauser Home Diary assessments.
Secondary outcomes, all measured on the same timescale as the primary outcome, are:
